Sanofi reported double-digit sales growth in Q2 2026
Sales grew 17.8% CER, business EPS up 33.3%, and 2026 guidance upgraded.
See the latest news and media coverage for Sanofi. We track all announcements, press releases, and industry mentions in real time, all in one place.
R&D-driven, AI-powered biopharmaceutical company
sanofi.comLast updated
In short: Sanofi raised its 2026 sales guidance following strong Q2 results and the success of Dupixent, despite pipeline and regulatory challenges.
Sales grew 17.8% CER, business EPS up 33.3%, and 2026 guidance upgraded.
The decision follows a strategic pipeline review, as the drug didn't show meaningful improvement over standard care.
The new committee, effective September 1, 2026, includes key leaders across businesses and R&D.
It is the first anticancer treatment administered via an on-body injector, offering similar efficacy with shorter treatment time.
Sanofi stock reflects solid first-quarter 2026 momentum as revenue and earnings grow on specialty medicines and vaccines, while the company continues to refine its strategic...
Regeneron & Sanofi discuss expanding partnership, potentially including Dupixent follow-ons. CEOs Schleifer & Garijo cite need to rebuild trust amid ongoing litigation.
Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full details...
On July 30, 2026, Sanofi SA (SNY) experienced a significant stock drop of 9% during European...
Track Sanofi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Sanofi and other trending companies.